How do you approach patients with driver mutation positive, Stage IV NSCLC who don't benefit from upfront first-line TKI?

It depends on the mutation.

EGFR mutants after Osimertinib:

- If oligometastatic disease: an option is radiation to the oligometastatic spots and continue osimertinib. It is important to re-biopsy as well due to the possibility of small cell transformation. If transformed to small cell, in general, c...